

# TIDES EUROPE

## Oligonucleotide & Peptide Therapeutics

12-14 NOVEMBER, 2024  
HAMBURG, GERMANY

Hamburg Congress Centre

# The Industry's Leading Event in Europe to Accelerate Therapeutics to Market

Expedite your R&D, improve your  
CMC efficiency, and build new partnerships

Register by 23 August to save £800! →

[TIDSEuropeEvent.com](https://TIDSEuropeEvent.com)

# Europe's Flagship Meeting For Oligonucleotide And Peptide Science, Technology And Networking




**600+**  
Industry Experts

Fast-track your products to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from Europe, North America and Asia.



**100+**  
Case Studies And New  
Data Presentations

Apply best practices and lessons learned from industry leaders working across the entire spectrum from discovery to clinic to CMC to manufacturing.



**85+**  
Leading Exhibitors

Connect with leading manufacturing, technology, and service providers to drive your promising therapeutic towards commercial success.

## What's New This Year?

### New Sessions:

Case Studies of Innovations and Efficiencies in Oligonucleotide CMC

Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs

Targeted Delivery of Oligonucleotides and Preclinical Progress

Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls

Leveraging mRNA as A Broad Therapeutic Platform: Oncology & Beyond

### New Workshops:

Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program

Synthesis and Characterization of Long sgRNA for CRISPR/Cas

8:30 **Registration and Coffee**

**Optional Pre-Conference Morning Workshops | 09:00-12:00**

9:00 **Workshop #1: Synthesis, CMC and Characterization of Long and Complex Oligonucleotides**

**Workshop Moderators:**

Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany  
Chris Oswald, Owner & Principal, Coswald Consulting, USA

**Workshop Description:**

The workshop will give an overview of manufacturing processes and CMC strategies for long and complex oligonucleotides, like sgRNA or aptamers. It will emphasize the CMC development from early discovery phase throughout the clinical phases and spotlight on cleaning/carryover, process development, analytical development, raw materials selection and control, impurity characterization, analytical tools and setting of specifications. The workshop will be split into a manufacturing-focused part ranging from early process development to scale-up, and an analytical part addressing process-, and product-related impurity formation and their control. After the presentations the speakers will jointly chair a panel discussion on CMC aspects.

**Topics to be Discussed:**

- CMC activities for long and complex oligonucleotide therapeutics or theranostics
- Raw material selection and control
- Understanding and controlling process and product-related impurities
- Analytical tools and their application

**Who Should Attend?**

Anyone interested in CMC, Impurity Control Strategies, and in-house or outsourced manufacturing of oligonucleotide therapeutics during pre-clinical and clinical development of synthetic RNA Therapeutics or Theranostics. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management

## Optional Pre-Conference Morning Workshops | 09:00-12:00

### 9:00 **Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program**

#### **9:00 Workshop Co-Moderators' Welcome and Opening Remarks**

Judy Carmody, Ph.D., Founder and Principal Consultant, Carmody Quality Solutions, LLC, USA

Melanie Cerullo, Chief Quality & Regulatory Officer, RecBioPharm, USA

#### **9:05 CMC Strategies to Accelerate Development Whilst Not Sacrificing Quality**

Judy Carmody, Ph.D., Founder and Principal Consultant, Carmody Quality Solutions, LLC, USA

#### **10:20 Networking Refreshment Break**

#### **10:45 A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program**

Melanie Cerullo, Chief Quality & Regulatory Officer, RecBioPharm, USA

#### **12:00 Close of Workshop**

#### **Topics to Be Discussed:**

- Development and Manufacturing Considerations: We will spotlight the critical points along the road in plasmid DNA, drug substance, and drug product process and analytical development and GMP manufacturing
- Regulatory and Quality Assurance: We will address the regulatory hurdles and how to navigate in the early phase landscape while still ensuring patient safety and successful IND submission
- Stability – how much and timing
- Setting Specifications for starting materials (plasmids), mRNA, sgRNA and LNP-DP
- How much detail is needed in the IND
- Future Perspectives

#### **Who Should Attend?**

Anyone interested in CMC, Impurity Control Strategies, Manufacturing of oligonucleotide therapeutics and Quality Assurance during pre-clinical and clinical development of chemical RNA Therapeutics or Theranostics. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development

<b>Optional Pre-Conference Morning Workshops   09:00-12:00</b>			
9:00	<p><b>Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides</b></p> <p><b>Workshop Moderators:</b>            Bruce Morimoto, Ph.D., Vice President, Drug Development, Alto Neuroscience, USA            Alastair Hay, Ph.D., Vice President, Peptides, Almac, United Kingdom</p> <p><b>Workshop Overview:</b>            Over the last 20 years, peptide therapeutics have evolved from simple to complex. Peptide modifications are very common including the incorporation of unnatural amino acids, conjugation, and cyclization. This workshop will consist of a collection of presentations with a focus on various peptide modification chemistries leading to improve metabolic and therapeutic properties with a focus on case studies as examples of these approaches and applications.</p>		
<b>Luncheon Spotlight Presentations</b>			
12:00	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>WuXi TIDES</b></p> </div> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>ST PHARM</b></p> </div> </td> </tr> </table>	<p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>WuXi TIDES</b></p> </div>	<p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>ST PHARM</b></p> </div>
<p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>WuXi TIDES</b></p> </div>	<p><b>Spotlight Presentation</b></p> <div style="text-align: center;">  <p><b>ST PHARM</b></p> </div>		
<b>Main Conference   Keynote Session</b>			
13:10	<p><b>Chairperson's Remarks</b></p>		
13:15	<p><b>Discovery of RNA-modifying Ribozymes</b>            Claudia Höbartner, Ph.D., Professor of Organic Chemistry, University of Würzburg, Germany</p>		

# Agenda | Tuesday 12, November 2024

## Main Conference | Keynote Session

13:45 **How Novo Nordisk is Expanding our Technology Platforms Via Strategic Internal and External Investments**  
Karina Thorn, Ph.D., Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT), Novo Nordisk, Denmark

14:15 **Designing the Once-Weekly and Oral GLP-1 Semaglutide**  
Jesper Lau, Ph.D., Vice President, Digital Science & Innovation, Novo Nordisk A/S, Denmark

14:45 **Networking Refreshment Break in Poster and Exhibit Hall**

15:15 **Discovery of Zosurabalpin**  
Patrizio Mattei, Ph.D., Expert Scientist, Medicinal Chemistry, F. Hoffmann-La Roche Ltd., Switzerland

16:00 **An Update on Lilly's siRNA & RNA Editing Portfolio**  
Maire Fiona Jung, Ph.D., VP & CSO, RNA, Lilly Institute of Genetic Medicine, Eli Lilly and Company

16:30 **n-Lorem Foundation: A Dream of Hope and Treatment for Nano-rare Patients Being Realized**  
Stanley Crooke, M.D., Ph.D., Founder and CEO, n-lorem Foundation, USA

17:00 **Networking Reception in Poster and Exhibit Hall**  
Join fellow attendees, speakers, exhibitors, and poster presenters for a fun evening of scientific exchange and networking in the exhibit hall.

18:30 **Close of Day One**

7:30	<b>Morning Spotlight Presentation</b>		
	<b>Spotlight Presentation</b> 		
	<b>Oligonucleotide Discovery, Preclinical and Clinical</b>	<b>Oligonucleotide Chemistry, Manufacturing &amp; Controls</b>	<b>Peptide Discovery to CMC</b>
	<b>Oligonucleotide Preclinical and Clinical Updates</b>	<b>Case Studies of Innovations and Efficiencies in Oligonucleotide CMC</b>	<b>Trends in Peptide Discovery and Synthesis</b>
8:00	<b>Chairperson's Remarks</b> Yogesh Sanghvi, Ph.D., President, Rasayan, Inc., USA	<b>Chairwoman's Remarks</b> Sonja Merkas, Ph.D., Founder, Livinovea, Switzerland	<b>Chairman's Remarks</b> Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna, Austria
8:05	<b>New Weapons Against Multidrug Resistant Bacterial Infections via an RNA Therapeutics Antibiotic Drug Discovery Platform</b> Peter Nielsen, Ph.D. Professor and Head of Center for Peptide-Based Antibiotics, University of Copenhagen, Denmark	<b>Scaling Up Solution Phase Oligo Manufacturing and Future Innovations</b> Yannick Fillon, Ph.D., Head of Oligonucleotide Process Chemistry, Biogen, USA	<b>Discovery and Development of Disulfide-constrained Peptides</b> Christina I. Schroeder, Ph.D., Senior Fellow, Peptide Therapeutics, Genentech, USA
8:35	<b>Using the L-stereoisomer RNA Aptamer NOX-A12 to Enhance Efficacy in Solid Tumors</b> Aram Mangasarian, Ph.D., Chief Executive Officer, TME Pharma, Germany	<b>Biocatalytic Approaches to Oligonucleotides Manufacturing, a CMC Perspective</b> Filippo Sladojevich, Ph.D., Senior Principal Scientist, Hoffmann-La Roche, Switzerland	<b>Development of Membrane-Permeable Cyclic Peptides</b> Christian Heinis, Ph.D., Associate Professor, Institute of Chemical Sciences and Engineering, EPFL, Switzerland
9:05	<b>Oligonucleotide IMT504, a Drug Candidate for Complex Regional Pain Syndrome. Preclinical and Phase-I Clinical Results</b> Alejandro Montaner, Ph.D., CEO, Immunalgia Therapeutics, Argentina	<b>Designing a Safe, Sustainable, and Efficient Drug Manufacturing Processes for Oligonucleotide Based Products</b> Ashish Garg, Ph.D., Director, Drug Product Development, Bioproduct Research and Development, Eli Lilly and Company, USA	<b>Targeting Membrane-bound Proteins Using Cell-based Biopanning of Cyclized CLIPS™</b> Peptides in Phage-displayed Libraries Sheena Ong, Scientist, Biosynth

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Preclinical and Clinical Updates	Case Studies of Innovations and Efficiencies in Oligonucleotide CMC	Trends in Peptide Discovery and Synthesis
9:35	<b>Networking Refreshment Break in Poster and Exhibit Hall</b>		
10:15	<b>Antisense Oligonucleotides for Treatment of Cancer and Kidney Diseases</b> Frank Jaschinski, Ph.D., Chief Scientific Officer, Secarna Pharmaceuticals, Germany	<b>Plant Design and Manufacturing Challenges with Insights from Leqvio</b> Letizia Volpe, Ph.D., Site MS&T Head Chemical Operations, Novartis, Switzerland	<b>Development of HER-096 as a Disease Modifying Therapy for Parkinson's Disease</b> Antti Vuolanto, Chief Executive Officer, Herantis Pharma plc, Finland
10:45	<b>RNA Therapies in Heart Failure - An Update</b> Thomas Thum, M.D., Ph.D., CSO, CMO and Founder, Cardior Pharmaceuticals, Germany	<b>NMR Platform Methods for Content and Loop Structure of Oligonucleotides</b> Joan Malmstrøm, Ph.D., Principal Scientist, CMC Analytical Support, Novo Nordisk A/S, Denmark	<b>Development of GUBamy, A Clinical Stage Long-acting Amylin Analogue Formulated at Neutral pH, Using StreamLine - A ML-driven Peptide Drug Discovery Platform</b> Morten Lundh, Ph.D., Director, Drug Discovery Innovation, Gubra A/S, Denmark
11:15	<b>Clinical Update on Rugonersen</b> Erich Koller, Ph.D., Senior Principal Scientist, Roche Innovation Center Basel, Switzerland	<b>Panel Discussion: Process Development &amp; Manufacturing of Oligos</b> <b>Moderator:</b> Sonja Merkas, Ph.D., Founder, Livinovea, Switzerland <b>Panelists:</b> Yannick Fillon, Ph.D., Head of Oligonucleotide Process Chemistry, Biogen, USA Filippo Sladojevich, Ph.D., Senior Principal Scientist, Hoffmann-La Roche, Switzerland Ashish Garg, Ph.D., Director, Drug Product Development, Bioproduct Research and Development, Eli Lilly and Company, USA Letizia Volpe, Ph.D., Site MS&T Head Chemical Operations, Novartis, Switzerland	<b>Targeted Innate Immune Stimulators as Therapeutics</b> Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna, Austria

11:45	<b>Transition to Spotlight Presentations</b>		
11:50	<b>Oligo Manufacturing Innovations – From Synthesis through Concentration</b> Tom Krebstakies, Ph.D., Sales Manager - Europe & Asia, Asahi Kasei Bioprocess  	<b>Spotlight Presentation</b>  	<b>Spotlight Presentation</b>  
12:20	<b>Networking Luncheon in Poster and Exhibit Hall</b>		
	<b>Spotlight Presentations</b>		
13:25	<b>The Latest Tools for the Characterization of mRNA and Oligonucleotide Biopharmaceuticals by CE and LC-MS</b> Stephen Lock, Ph.D., Senior Market Development Manager, Biopharma, EMEA, SCIEX  	<b>Spotlight Presentation</b>  	<b>Spotlight Presentation</b>  
	<b>Oligonucleotide Discovery, Preclinical and Clinical</b>	<b>Oligonucleotide Chemistry, Manufacturing &amp; Controls</b>	<b>Peptide Discovery to CMC</b>
	<b>Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical</b>	<b>Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs</b>	<b>Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls</b>
13:55	<b>Chairman's Remarks</b> Troels Koch, Ph.D., Chief Technology Officer, MiNa Therapeutics, Denmark	<b>Chairman's Remarks</b> Daniel Waschke, Ph.D., Technical Regulatory Manager, F. Hoffmann-La Roche Ltd., Switzerland	<b>Chairman's Remarks</b> Riccardo Bernasconi, Ph.D., Director Business Development, Bachem, Switzerland

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	<b>Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical</b>	<b>Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs</b>	<b>Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls</b>
14:00	<b>Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications</b> Gerard Platenburg, Ph.D., Chief Scientific Officer, ProQR Therapeutics, The Netherlands	<b>An Update on EMA Regulatory Guidelines for Oligonucleotides</b> René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical Devices, Germany (Invited)	<b>How to Develop a Close-to-commercial Manufacturing Process for Peptide Drug Substance</b> Gajan Santhakumar, Ph.D., Associate Principal Scientist, Early Chemical Development, AstraZeneca, United Kingdom
14:30	<b>Increasing ASO Stability with Chemical Modifications</b> Erich Koller, Ph.D., Senior Principal Scientist, Roche Innovation Center Basel, Switzerland	<b>How to Prepare for a Successful IND/IMPd When Developing Oligonucleotide Therapeutics</b> Hagen Cramer, Ph.D., Chief Technology Officer, QurAlis, USA	<b>Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand</b> Olivier Ludemann-Hombourger, Ph.D., Director, Global Innovation and Technology, PolyPeptide, France
15:00	<b>Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS</b> Beatriz Llamusi, Ph.D., Chief Scientific Officer & Co Founder, Arthex Biotech S.L., Spain	<b>General Post-approval Observations and Trends in Oligo Programs from a Regulatory Perspective</b> Tracey Burr, Ph.D., Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals, USA	<b>A Generalized PAT Approach for Fast Peptide Purification Process Development and Production Control in CMC Settings</b> Jörg Kittelmann, Ph.D., Principal Scientist, CMC Downstream API Development, Novo Nordisk, Denmark
15:30	 <b>Networking Refreshment Break in Poster and Exhibit Hall</b> <div style="float: right; text-align: right;">           Afternoon Beer Sponsor  </div>		
16:15	<b>AIC468 - A Novel Antisense Oligonucleotide in Clinical Development for Treatment of BKV Infections</b> Holger Zimmermann, Ph.D., Chief Research and Development Officer, AiCuris Anti-infective Cures AG, Germany Eric van der Veer, Ph.D., Chief Innovation Officer, Hybridize Therapeutics, The Netherlands	<b>Regulatory CMC Insights on Post-approval Changes for a siRNA Oligonucleotide</b> Daniela Fischer, Ph.D., Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing, Switzerland	<b>Bachem CMC Presentation</b> Bachem Speaker TBA

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	<b>Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical</b>	<b>Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs</b>	<b>Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls</b>
16:45	<b>State of the Art siRNA - Delivery and Chemistry</b> Tomaz Einfalt, Principal Investigator II xRNA, Novartis Institutes for BioMedical Research, Switzerland	<b>Enzymatic Ligation, Regulatory Challenges and Potential Platform Approaches</b> Sergey Tsukanov, Ph.D., Senior Director - Oligonucleotides, Synthetic Molecule Design & Development, Eli Lilly and Company, USA	<b>Improving Efficiencies in Peptide API Process Development</b> Yi Yang, Ph.D., Principal Scientist, Ferring Pharmaceuticals A/S, Denmark
17:15	 <b>Evening Networking Reception in Hamburg</b> This evening's networking reception will take place in a venue close to the TIDES Europe conference center. Join fellow attendees and speakers for drinks and small bites for a fun start to your evening out in Hamburg.		
19:00	<b>Close of Day Two</b>		

7:30	<b>Morning Spotlight Presentation</b>		
	<b>Enhancing the Activity and Delivery of Oligonucleotide Therapeutics with Modified Phosphoramidites and Nucleotides</b> Xavier Gerard, Ph.D., Field Application Scientist, EMEA, Nucleic Acid Therapeutics (NATx) Division, Thermo Fisher Scientific, Switzerland  		
	<b>Oligonucleotide Discovery, Preclinical and Clinical</b>	<b>Oligonucleotide Chemistry, Manufacturing &amp; Controls</b>	<b>Peptide Discovery to CMC</b>
	<b>Leveraging Advances in mRNA and Genome Editing</b>	<b>Advances in Oligonucleotide Analytics and Characterization</b>	<b>Innovations in Peptide Discovery, Design and Peptide CMC</b>
8:00	<b>Chairperson's Remarks</b> Christoph Kroener, Ph.D., Senior Director CMC IVAC Portfolio, BioNTech AG, Germany	<b>Chairperson's Remarks</b> Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma	<b>Chairman's Remarks</b>
8:05	<b>Individualized Cancer Treatment Using mRNA Technology</b> Christoph Kroener, Ph.D., Senior Director CMC IVAC Portfolio, BioNTech AG, Germany	<b>From LC-UV to MS-based Methodology for the Analysis of siRNA</b> Anthony Ehkirch, Ph.D., Principal Scientist and Analytical Expert, Novartis, Switzerland	<b>Macrocyclic Peptides as Scaffolds in Drug Design</b> David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland, Australia
8:35	<b>Building a Platform Suitable for mRNA Therapeutics</b> George Thom, Director, mRNA Team Leader, AstraZeneca, United Kingdom	<b>Unlocking Guide RNA Quality: The Power of NGS Analysis</b> Barbara Pfaff, Ph.D., QC Manager Molecular Sequencing, BioSpring GmbH, Germany	<b>Switching off Transcription Factors Using Intracellular Library-derived Peptides</b> Jody Mason, Ph.D., Professor of Biochemistry, University of Bath, United Kingdom

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	<b>Leveraging Advances in mRNA and Genome Editing</b>	<b>Advances in Oligonucleotide Analytics and Characterization</b>	<b>Innovations in Peptide Discovery, Design and Peptide CMC</b>
9:05	<b>Next Generation Lipid Nanoparticles for mRNA delivery</b> Vusala Ibrahimova, Ph.D., Research Scientist, CureVac SE, Germany	<b>Optimization of the Solid-phase Oligonucleotide Detritylation Reaction Using In-line IR PAT</b> Steven Stanton, Senior Scientist, Oligonucleotide Process Chemistry, AstraZeneca, United Kingdom	<b>Development of DMF-free SPPS Processes</b> Trine Puggaard Petersen, Ph.D., Senior, Development Scientist, Novo Nordisk, Denmark
9:35	<b>Networking Refreshment Break in Poster and Exhibit Hall</b>		
10:15	<b>In vivo Genome Editing: Translating Science from Bench to Bedside</b> Zi Jun Emma Wang, Ph.D., Chief Technology Officer, YolTech Therapeutics, China	<b>Characterization of siRNA Product-related Impurities by HILIC</b> Lucas Bethge, Ph.D., VP, Group Leader Oligonucleotide Chemistry, Silence Therapeutics, Germany	<b>Flow SPPS - Towards Greener and More Efficient Peptide Manufacturing</b> Eike-Fabian Sachs, Head of Development Frankfurt, CordenPharma International GmbH, Germany
10:45	<b>Enhancing CRISPR/Cas9 Gene Editing in Lung Tumor Cells: Optimization of Lipid Nanoparticles for Potential Inhalation Therapy</b> Simone Carneiro, Ph.D., Postdoctoral Fellow, LMU Munich, Germany	<b>The Role of Digital Data Analytics (DDA) in Escalating GSK's Bepiroversin Analytical Development Procedures</b> Marah Faron, Digital Innovation Lead, GSK, United Kingdom	<b>Get Rid of Side Reactions on Cys and Met Residues During SPPS and Cleavage</b> Beatriz de la Torre, Ph.D., Research Professor, Laboratory of Medicine and Medical Sciences, University of KwaZulu- Natal, South Africa
11:15	<b>Delivery of Genomic Medicines</b> Luis Brito, Ph.D., Vice President, Delivery Platform, Beam Therapeutics, USA	<b>Big Molecules and Small Particles</b> Lennart Lindfors, Ph.D., Senior Principal Scientist, Pharmaceutical Sciences, Pharmaceutical R&D, AstraZeneca, Sweden	<b>Atom Economy and Sustainable Strategies in SPPS</b> Walter Cabri, Ph.D., Full Professor of Organic Chemistry, University of Bologna, Italy

11:45	<b>Transition to Spotlight Presentations</b>		
11:50	<p><b>Oligonucleotides &amp; Chromatography – What’s New?</b> Patrick Endres, Manager, Product Management EMEA, Tosoh Bioscience GmbH, Germany</p> 	<p><b>BROTHERS: A Proprietary Antisense Oligonucleotide Platform for the Treatment of a Broader range of Diseases</b> Tsuyoshi Yamamoto, Ph.D., CSO, Liid Pharmaceuticals and Associate Professor, Nagasaki University</p> 	<p><b>Spotlight Presentation</b></p> 
12:20	<b>Networking Luncheon in Poster and Exhibit Hall</b>		
13:25	<p><b>Enzymatic Oligonucleotide Manufacturing Combination with Solution Based Approach AJIPHASE® for Large Scale</b> Daisuke Takahashi Ph.D., Executive Specialist, Ajinomoto Co. Inc., Japan</p> 	<p><b>Leveraging NMR Spectroscopy for High-resolution Structure Characterization of TIDES</b> Victor Beaumont, Ph.D., Strategic Market Development Specialist, Bruker UK Limited</p> 	<p><b>Spotlight Presentation</b></p> 
	<b>Oligonucleotide Discovery, Preclinical and Clinical</b>	<b>Oligonucleotide Chemistry, Manufacturing &amp; Controls</b>	<b>Peptide Discovery to CMC</b>
	<b>Targeted Delivery of Oligonucleotides and Preclinical Progress</b>	<b>Advances in Oligonucleotide Manufacturing</b>	<b>Innovations in Peptide Discovery, Design and Peptide CMC</b>
13:55	<p><b>Chairman’s Remarks</b> Jim Weterings, Ph.D., Vice President Research, RNA Therapeutics &amp; Delivery, Sirnaomics, USA</p>	<p><b>Chairman’s Remarks</b></p>	<p><b>Chairman’s Remarks</b></p>

# Agenda | Thursday 14, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	<b>Targeted Delivery of Oligonucleotides and Preclinical Progress</b>	<b>Advances in Oligonucleotide Manufacturing</b>	<b>Innovations in Peptide Discovery, Design and Peptide CMC</b>
14:00	<b>Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration</b> Jing Chen, Ph.D., Director of Discovery DMPK, Arrowhead Pharmaceuticals, USA	<b>Nitto CMC Presentation</b> Nitto Avecia Speaker TBA	<b>An Update on EMA Regulatory Guidelines for Peptides</b> René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical, Devices, Germany (Invited)
14:30	<b>Design and Application of Novel Peptide Conjugates for the Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cells</b> Laurent Knerr, Ph.D., Principal Scientist, AstraZeneca, Sweden	<b>Manufacturing of Long Oligos for Gene Editing, From HTP to GMP</b> Fred Briones, Ph.D., Director, Oligonucleotide Chemistry, Tessera Therapeutics, USA	<b>Pharmaceutical Industry Feedback and Reflections on EMA Draft Guideline for Development and Manufacture of Synthetic Peptides</b> Osama Chahrour, Ph.D., Principal Scientist, Chemical Development, AstraZeneca, United Kingdom
15:00	<b>GlycoConnect Antibody-oligonucleotide Conjugates for Targeted Treatment of Neuromuscular Diseases</b> Floris van Delft, Ph.D., Head of R&D, SynAffix/Lonza, The Netherlands	<b>Charting New Horizons in guide RNA Manufacturing</b> Thi Lan Phuong Pham, Project Lead GMP and Large Scale Production, BioSpring GmbH	<b>Peptide Synthesis Strategies for Production of Commercial GLP-1</b> Vera D'Aloisio, Ph.D., Sales Manager Europe, AmbioPharm, United Kingdom
15:30	<b>Networking Refreshment Break in Poster and Exhibit Hall</b>		
16:00	<b>GalAhead™ muRNA: A Proprietary GalNAc-RNAi Therapeutic Platform for Simultaneous Downregulation of Multiple Genes</b> Jim Weterings, Ph.D., Vice President Research USA, RNA Therapeutics & Delivery, Sirnaomics, USA	<b>Challenges of Generic Oligonucleotide Drug Substance Development</b> Michael Tikhonov, Analytical Group Manager, Oligonucleotides and Peptides, Teva, Israel Daniel Pinchuk, Ph.D., Oligonucleotide Team Leader, Chemical R&D, Teva, Israel	<b>Opportunities and Challenges in the Large-Scale Manufacturing of Peptide APIs</b> Jyothi Thundimadathil, Ph.D., Director of Drug Substance Development CMC, Carmot Therapeutics, USA

# Agenda | Thursday 14, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	<b>Targeted Delivery of Oligonucleotides and Preclinical Progress</b>	<b>Advances in Oligonucleotide Manufacturing</b>	<b>Innovations in Peptide Discovery, Design and Peptide CMC</b>
16:30	<b>Delivery of Therapeutic RNAs into the Brain</b> Ekkehard Leberer, Ph.D., Professor of Biochemistry and CEO, ELBIOCON, Germany	<b>Oligonucleotide Solution API: Navigating the Regulatory Landscape</b> Chris Chorley, Associate Director, Regulatory Affairs CMC, Biogen	<b>Safety-Catch Solid-Phase Resins for Peptide Cleavage in the Absence of Acids</b> Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africa
17:00	<b>Delivery of Therapeutic siRNAs to Skin and Muscle Using Hydrophobic Conjugates</b> Julia Alterman, Ph.D., Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical School, USA	<b>Late Breaking Presentation</b>	<b>Late Breaking Presentation</b>
17:30	<b>Close of Conference</b>		

# Meet The People Behind The Products & Get The Answers You Need

## PLATINUM SPONSORS



## GOLD SPONSORS



## SILVER SPONSORS



## BRONZE SPONSORS



## Exhibitors

ADS Biotec	Hongene Biotech Corp	Scharlab
Almac Group	Inabata	ScinoPharm
Aspen Oss BV	Jiuzhou Pharma	Senn Chemicals
Asymchem	K&A Labs GmbH	Shenzhen Readline Technology
Aurisco	Kinovate Life Sciences	Sinopeg
BCN Peptides	Metabion International	Sousekai
Bio-Works	Milestone	Syncrest
BioPharmaSpec	Mitsui	Synoligo
Biosolve	Nankai Hecheng	Tosoh Bioscience
ChemGenes	Neuland Labs	TriLink Technologies
CPC Scientific	Nippon Shokubai	UFAG Laboratorien
CSBio	OPTIMA packaging group GmbH	U-genes
Dottikon Exclusive Synthesis	Orilife Biopharma	Vapourtec
Euroapi	PeptiSystems	W.L.Gore
Eurogentec	Phenomenex	Wuhu Huaren Science & Technology
Glen Research	Pukang Biotechnology	Yamasa
Glycogene	Quality Assistance	YMC ChromaCon
Gyros Protein Technologies	RiboBay	Ypso-Facto
Hanbon Science & Technology	RiboBio	ZY Biochemical Technology
Hera BioLabs	RIBOPRO	
	Sapala	

For more information on how you can connect with key buyers at TIDES Europe, contact:

#A-F: Jennifer Wickett, Phone: +1 (212) 600-3452

E-mail: [Jennifer.Wickett@informa.com](mailto:Jennifer.Wickett@informa.com)

G-Z: Michael Moriarty, +1 (646) 895-7412

E-mail: [michael.moriarty@informa.com](mailto:michael.moriarty@informa.com)

# 2024 Pass Benefit Comparison

## What's included in your pass

	Main Conference	Main Conference & Workshop Pass	Digital Experience Pass
All live in-person scientific presentations from world-renowned speakers	✓	✓	✗
60+ live booths in the exhibit hall	✓	✓	✗
Live poster presentations in poster hall	✓	✓	✗
Daily networking lunches and refreshment breaks	✓	✓	✗
All in-person live pre-conference workshops held	✗	✓	✗
1 year on-demand access to all approved main conference sessions	✓	✓	✗
Digital networking opportunities throughout the event	✓	✓	✓
All approved recordings of presentations from the in-person event	✓	✓	✓
Virtual exhibit and poster hall which consists of majority of vendors and poster presenters from live event	✓	✓	✓
The full attendee list (both live and digital only attendees) with capability to video chat, instant message and request meetings	✓	✓	✓

# 2024 Registration and Attendance Information

IN-PERSON PASS	SAVE £800 Register by 23 August, 2024	
	DISCOUNT	STANDARD RATE
<b>Industry Rates</b>		
Main Conference + Pre-conference Workshop	£2,899	£3,699
Main Conference Only	£2,499	£3,299
<b>Academic/Govt Rates*</b>		
Main Conference + Pre-conference Workshop	£1,499	£1,599
All Access Conference Pass	£1,099	£1,199

\*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

DIGITAL PASS	SAVE £600 Register by 23 August, 2024	
	DISCOUNT	STANDARD RATE
<b>Industry Rates</b>		
Main Conference + Pre-conference Workshop	£2,499	£3,099
Main Conference Only	£2,099	£2,699
<b>Academic/Govt Rates*</b>		
Main Conference + Pre-conference Workshop	£1,399	£1,499
All Access Conference Pass	£999	£1,099

\*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

[View Registration Options](#)

## Poster Presentations

Share your company's scientific research by presenting a poster at TIDES Europe 2024. Be sure to sign up for a poster space when you register. Visit our [poster page](#) to learn more.

## Venue

CCH - Congress Center Hamburg  
Congresspl. 1, 20355 Hamburg, Germany  
Phone: +49 40 35690

## Group Discounts:

Register a group of 3+ to receive additional savings.

To register your group, please contact:

**Tayla Thomas**  
Tayla.Thomas@informa.com  
+44 (0) 20 8052 1571

## Also Consider Attending

### TIDES Asia 2024

26-28 Feb, 2025  
Westin Miyako Kyoto  
Kyoto, Japan

### TIDES USA 2025

May 19-22, 2025  
Manchester Grand Hyatt San Diego  
San Diego, CA

**3 WAYS TO REGISTER**



**ONLINE:**  
[TIDSEuropeEvent.com](https://TIDSEuropeEvent.com)



**CALL**  
+44 (0) 20 8052 1571



**EMAIL**  
[register@informa.com](mailto:register@informa.com)